indiamed
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
facebook x icon x icon linkedin linkedin
all-news

Chemotherapy drug outperforms remdesivir against coronavirus in lab experiments: Study

IMT News Desk
The researchers identified four promising drugs, which were then tested against the SARS-CoV-2 virus in lab experiments A chemotherapy medication originally developed to treat cancer could potentially be repurposed to inhibit the replication of the novel coronavirus and treat COVID-19, according to a study based on computer simulations and lab experiments. The research, published in the journal PLOS Computational Biology, combined multiple computational techniques that simulate drug-virus interactions from different, complementary perspectives. Using this hybrid approach, scientists from the Shenzhen Institutes of Advanced Technology in China, screened 1,906 existing drugs for their potential ability to inhibit replication of the coronavirus by targeting a viral protein called RNA-dependent RNA polymerase (RdRP). The researchers identified four promising drugs, which were then tested against the SARS-CoV-2 virus in lab experiments. They said two of the drugs, pralatrexate and azithromycin, successfully inhibited replication of the virus, and further lab experiments showed that pralatrexate more strongly inhibited viral replication than did remdesivir -- a drug that is currently used to treat some COVID-19 patients. According to the scientists, the findings suggest that pralatrexate could potentially be repurposed to treat COVID-19. However, the researchers said the chemotherapy drug may prompt significant side effects and is used for people with terminal lymphoma, so they added that immediate use for COVID-19 patients is not guaranteed. But the research highlighted the importance of the new screening strategy to identify drugs that could be repurposed. "We have demonstrated the value of our novel hybrid approach that combines deep-learning technologies with more traditional simulations of molecular dynamics," said study author Haiping Zhang of the Shenzhen Institutes of Advanced Technology. The researchers are now developing additional computational methods for generating novel molecular structures that could be developed into new drugs to treat COVID-19.  PTI

Recommended

Precision Oncology Goes Local: 4baseCare’s Genomics Lab and Atlas Set to Transform Cancer Care

India solidifies position as most attractive global CDMO destination: LoEstro Report

IKS Health achieves HITRUST r2 recertification

Wockhardt Hospitals launches My Patient, My Idea initiative for nurses

Granules India extends CSR activity for TB patients

Dr Vinay Munikoty Venkatesh joins SIOP as South India’s Country Ambassador

Biocon to Invest $200 Million This Year in Growth and Expansion

Young Lifters, Old Hips: Steroids and Powder Use Fuel Hip Damage in 20s

Indiamedtoday

A premier media platform empowering healthcare professionals with critical business insights, news, and innovations to excel in a rapidly evolving industry.

EMAIL editorial@indiamedtoday.com

EMAIL sales@indiamedtoday.com

quick links

news health it interview opinion strategy magazine privacy policy terms and conditions

subscribe to our newsletter

Stay updated with the latest breakthroughs in Indian healthcare, medical research, and wellness insights.

    follow us

    facebook x icon x icon linkedin linkedin
    Copyright © 2025 INDIAMED TODAY Marketed By Screetract Solutions